Literature DB >> 17690087

Pharmacologic considerations in the treatment of repetitive or prolonged seizures.

James Cloyd1.   

Abstract

Seizure emergencies are relatively common; however, in-hospital emergency care often is delayed by a variety of factors. Home-based treatment is effective at interrupting prolonged or repetitive seizures, but this option is underused despite its wide availability. The choice of agent used to treat seizure emergencies will depend chiefly on differences among the properties of the available drugs, particularly with regard to route of administration, lipid solubility, formulation characteristics, and the relative size of the absorptive surface area. These factors also can play a part in the decision to use one route of administration over another. Intravenous administration is the fastest and most reliable method of drug delivery, but alternative methods of drug delivery include oral, intramuscular, buccal, nasal, and rectal routes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690087     DOI: 10.1177/08830738070220050901

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Seizures in palliative care.

Authors:  Golda Tradounsky
Journal:  Can Fam Physician       Date:  2013-09       Impact factor: 3.275

2.  Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.

Authors:  Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman
Journal:  Epilepsy Curr       Date:  2016 Jan-Feb       Impact factor: 7.500

Review 3.  [S2k guidelines: status epilepticus in adulthood : Guidelines of the German Society for Neurology].

Authors:  F Rosenow; J Weber
Journal:  Nervenarzt       Date:  2021-03-22       Impact factor: 1.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.